 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || DR-01 / Dren Bio
New P1 trial: A Study of Subcutaneous DR-01 in Healthy Volunteers (clinicaltrials.gov) - Jan 9, 2025
P1, N=36, Not yet recruiting, Sponsor: Dren Bio
- DR-01 / Dren Bio
Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization (Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)) - Nov 6, 2024 - Abstract #ASH2024ASH_2458;
P1/2
An encouraging response rate including 3 durable CRs points to the potential for DR-01 as a viable treatment option for CTL. Study DR-01-ONC-001 is currently enrolling an international cohort of patients with CTL into phase 2, part B2 of the trial.
- ||| DR-01 / Dren Bio
Enrollment open: A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo (clinicaltrials.gov) - Oct 1, 2024
P1, N=60, Recruiting, Sponsor: Dren Bio
Study DR-01-ONC-001 is currently enrolling an international cohort of patients with CTL into phase 2, part B2 of the trial. Not yet recruiting --> Recruiting
- ||| DR-01 / Dren Bio
New P1 trial: A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo (clinicaltrials.gov) - Sep 20, 2024
P1, N=60, Not yet recruiting, Sponsor: Dren Bio
- cyclophosphamide / Generic mfg., methotrexate / Generic mfg., cyclosporine / Generic mfg.
DR-01, a Non-Fucosylated Anti-CD94 Antibody, Depletes Leukemic Cells in Ex Vivo and In Vivo Models of Large Granular Lymphocyte Leukemia (ENMCC - 391-392) - Nov 4, 2022 - Abstract #ASH2022ASH_5347;
Additional profiling and evaluation of DR-01 in LGLL patient samples ex vivo as part of a pre-phase I study is ongoing. A phase I/II trial has been initiated to assess the safety and efficacy of DR-01 in previously treated LGLL patients.
- | DR-01 / Dren Bio
New P1/2 trial: A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas (clinicaltrials.gov) - Jul 27, 2022
P1/2, N=69, Recruiting, Sponsor: Dren Bio